Advertisement

Index by author

October 01, 1996; Volume 50,Issue 4

A

  1. Abdel-Malek, S

    1. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
      W E Robinson, M Cordeiro, S Abdel-Malek, Q Jia, S A Chow, M G Reinecke and W M Mitchell
      Molecular Pharmacology October 1996, 50 (4) 846-855;

  2. Adams, M E

    1. Block of high-threshold calcium channels by the synthetic polyamines sFTX-3.3 and FTX-3.3.
      T M Norris, E Moya, I S Blagbrough and M E Adams
      Molecular Pharmacology October 1996, 50 (4) 939-946;

  3. Alahari, S K

    1. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
      S K Alahari, N M Dean, M H Fisher, R Delong, M Manoharan, K L Tivel and R L Juliano
      Molecular Pharmacology October 1996, 50 (4) 808-819;

B

  1. Backstrom, J R

    1. Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.
      H Canton, R B Emeson, E L Barker, J R Backstrom, J T Lu, M S Chang and E Sanders-Bush
      Molecular Pharmacology October 1996, 50 (4) 799-807;

  2. Bao, Y

    1. Structural determinants of substrates for the prostaglandin transporter PGT.
      S Itoh, R Lu, Y Bao, J D Morrow, L J Roberts and V L Schuster
      Molecular Pharmacology October 1996, 50 (4) 736-742; DOI: https://doi.org/10.1124/mol.50.4.736

  3. Barker, E L

    1. Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.
      H Canton, R B Emeson, E L Barker, J R Backstrom, J T Lu, M S Chang and E Sanders-Bush
      Molecular Pharmacology October 1996, 50 (4) 799-807;
    2. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter.
      E L Barker and R D Blakely
      Molecular Pharmacology October 1996, 50 (4) 957-965;

  4. Bass, R T

    1. Identification and characterization of novel somatostatin antagonists.
      R T Bass, B L Buckwalter, B P Patel, M H Pausch, L A Price, J Strnad and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 709-715;

  5. Beall, H D

    1. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
      D L Gustafson, H D Beall, E M Bolton, D Ross and C A Waldren
      Molecular Pharmacology October 1996, 50 (4) 728-735;

  6. Berg, K A

    1. 5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism.
      K A Berg, S Maayani and W P Clarke
      Molecular Pharmacology October 1996, 50 (4) 1017-1023;

  7. Bertrand, D

    1. Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino-terminal domain of the receptor.
      D Yu, L Zhang, J L Eiselé, D Bertrand, J P Changeux and F F Weight
      Molecular Pharmacology October 1996, 50 (4) 1010-1016;

  8. Birnbaumer, M

    1. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
      A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal
      Molecular Pharmacology October 1996, 50 (4) 820-828;

  9. Blagbrough, I S

    1. Block of high-threshold calcium channels by the synthetic polyamines sFTX-3.3 and FTX-3.3.
      T M Norris, E Moya, I S Blagbrough and M E Adams
      Molecular Pharmacology October 1996, 50 (4) 939-946;

  10. Blakely, R D

    1. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter.
      E L Barker and R D Blakely
      Molecular Pharmacology October 1996, 50 (4) 957-965;

  11. Bockaert, J

    1. Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists.
      J Gomeza, S Mary, I Brabet, M L Parmentier, S Restituito, J Bockaert and J P Pin
      Molecular Pharmacology October 1996, 50 (4) 923-930;

  12. Bolton, E M

    1. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
      D L Gustafson, H D Beall, E M Bolton, D Ross and C A Waldren
      Molecular Pharmacology October 1996, 50 (4) 728-735;

  13. Bourne, H R

    1. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation.
      B R Conklin, P Herzmark, S Ishida, T A Voyno-Yasenetskaya, Y Sun, Z Farfel and H R Bourne
      Molecular Pharmacology October 1996, 50 (4) 885-890;

  14. Brabet, I

    1. Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists.
      J Gomeza, S Mary, I Brabet, M L Parmentier, S Restituito, J Bockaert and J P Pin
      Molecular Pharmacology October 1996, 50 (4) 923-930;

  15. Bracamontes, J

    1. Endogenous subunits can cause ambiguities in the pharmacology of exogenous gamma-aminobutyric acidA receptors expressed in human embryonic kidney 293 cells.
      S Ueno, C Zorumski, J Bracamontes and J H Steinbach
      Molecular Pharmacology October 1996, 50 (4) 931-938;

  16. Brust, P F

    1. Functional coupling of rat group II metabotropic glutamate receptors to an omega-conotoxin GVIA-sensitive calcium channel in human embryonic kidney 293 cells.
      B A McCool, J P Pin, P F Brust, M M Harpold and D M Lovinger
      Molecular Pharmacology October 1996, 50 (4) 912-922;

  17. Buckwalter, B L

    1. Identification and characterization of novel somatostatin antagonists.
      R T Bass, B L Buckwalter, B P Patel, M H Pausch, L A Price, J Strnad and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 709-715;

  18. Burman, M

    1. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
      S Jacobitz, M M McLaughlin, G P Livi, M Burman and T J Torphy
      Molecular Pharmacology October 1996, 50 (4) 891-899;

C

  1. Canton, H

    1. Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.
      H Canton, R B Emeson, E L Barker, J R Backstrom, J T Lu, M S Chang and E Sanders-Bush
      Molecular Pharmacology October 1996, 50 (4) 799-807;

  2. Capranico, G

    1. Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
      C Sissi, G Capranico, E Menta and M Palumbo
      Molecular Pharmacology October 1996, 50 (4) 838-845;

  3. Chang, M S

    1. Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.
      H Canton, R B Emeson, E L Barker, J R Backstrom, J T Lu, M S Chang and E Sanders-Bush
      Molecular Pharmacology October 1996, 50 (4) 799-807;

  4. Changeux, J P

    1. Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino-terminal domain of the receptor.
      D Yu, L Zhang, J L Eiselé, D Bertrand, J P Changeux and F F Weight
      Molecular Pharmacology October 1996, 50 (4) 1010-1016;

  5. Chao, J

    1. Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit.
      K Williams, J Chao, K Kashiwagi, T Masuko and K Igarashi
      Molecular Pharmacology October 1996, 50 (4) 701-708;

  6. Chen, J C

    1. Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.
      S M Yu, S F Chen, Y T Lau, C M Yang and J C Chen
      Molecular Pharmacology October 1996, 50 (4) 1000-1009;

  7. Chen, S F

    1. Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.
      S M Yu, S F Chen, Y T Lau, C M Yang and J C Chen
      Molecular Pharmacology October 1996, 50 (4) 1000-1009;

  8. Chow, S A

    1. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
      W E Robinson, M Cordeiro, S Abdel-Malek, Q Jia, S A Chow, M G Reinecke and W M Mitchell
      Molecular Pharmacology October 1996, 50 (4) 846-855;

  9. Clarke, W P

    1. 5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism.
      K A Berg, S Maayani and W P Clarke
      Molecular Pharmacology October 1996, 50 (4) 1017-1023;

  10. Cloëz-Tayarani, I

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  11. Cohen, G M

    1. DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes.
      M MacFarlane, N A Jones, C Dive and G M Cohen
      Molecular Pharmacology October 1996, 50 (4) 900-911;

  12. Conklin, B R

    1. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation.
      B R Conklin, P Herzmark, S Ishida, T A Voyno-Yasenetskaya, Y Sun, Z Farfel and H R Bourne
      Molecular Pharmacology October 1996, 50 (4) 885-890;

  13. Cordeiro, M

    1. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
      W E Robinson, M Cordeiro, S Abdel-Malek, Q Jia, S A Chow, M G Reinecke and W M Mitchell
      Molecular Pharmacology October 1996, 50 (4) 846-855;

D

  1. Dean, N M

    1. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
      S K Alahari, N M Dean, M H Fisher, R Delong, M Manoharan, K L Tivel and R L Juliano
      Molecular Pharmacology October 1996, 50 (4) 808-819;

  2. Delong, R

    1. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
      S K Alahari, N M Dean, M H Fisher, R Delong, M Manoharan, K L Tivel and R L Juliano
      Molecular Pharmacology October 1996, 50 (4) 808-819;

  3. Dickson, J

    1. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
      A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal
      Molecular Pharmacology October 1996, 50 (4) 820-828;

  4. Ding, X

    1. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2a6: role in metabolic activation of nasal toxicants.
      C Liu, X Zhuo, F J Gonzalez and X Ding
      Molecular Pharmacology October 1996, 50 (4) 781-788;

  5. Dive, C

    1. DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes.
      M MacFarlane, N A Jones, C Dive and G M Cohen
      Molecular Pharmacology October 1996, 50 (4) 900-911;

  6. Dragatsis, I

    1. Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
      M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi
      Molecular Pharmacology October 1996, 50 (4) 985-993;

E

  1. Eiselé, J L

    1. Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino-terminal domain of the receptor.
      D Yu, L Zhang, J L Eiselé, D Bertrand, J P Changeux and F F Weight
      Molecular Pharmacology October 1996, 50 (4) 1010-1016;

  2. Emeson, R B

    1. Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.
      H Canton, R B Emeson, E L Barker, J R Backstrom, J T Lu, M S Chang and E Sanders-Bush
      Molecular Pharmacology October 1996, 50 (4) 799-807;

  3. Eusebi, F

    1. Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist.
      D Ragozzino, R M Woodward, Y Murata, F Eusebi, L E Overman and R Miledi
      Molecular Pharmacology October 1996, 50 (4) 1024-1030;

  4. Evans, C J

    1. Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors.
      E T Piros, P L Prather, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology October 1996, 50 (4) 947-956;

F

  1. Farber, J L

    1. The antioxidant function of the physiological content of vitamin C.
      P A Glascott, M Tsyganskaya, E Gilfor, M A Zern and J L Farber
      Molecular Pharmacology October 1996, 50 (4) 994-999;

  2. Farfel, Z

    1. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation.
      B R Conklin, P Herzmark, S Ishida, T A Voyno-Yasenetskaya, Y Sun, Z Farfel and H R Bourne
      Molecular Pharmacology October 1996, 50 (4) 885-890;

  3. Fillion, G

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  4. Fillion, M P

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  5. Fisher, M H

    1. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
      S K Alahari, N M Dean, M H Fisher, R Delong, M Manoharan, K L Tivel and R L Juliano
      Molecular Pharmacology October 1996, 50 (4) 808-819;

  6. Fugelli, A

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

G

  1. Georgoussi, Z

    1. Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
      M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi
      Molecular Pharmacology October 1996, 50 (4) 985-993;

  2. Gilfor, E

    1. The antioxidant function of the physiological content of vitamin C.
      P A Glascott, M Tsyganskaya, E Gilfor, M A Zern and J L Farber
      Molecular Pharmacology October 1996, 50 (4) 994-999;

  3. Glascott, P A

    1. The antioxidant function of the physiological content of vitamin C.
      P A Glascott, M Tsyganskaya, E Gilfor, M A Zern and J L Farber
      Molecular Pharmacology October 1996, 50 (4) 994-999;

  4. Gomeza, J

    1. Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists.
      J Gomeza, S Mary, I Brabet, M L Parmentier, S Restituito, J Bockaert and J P Pin
      Molecular Pharmacology October 1996, 50 (4) 923-930;

  5. Gonzalez, F J

    1. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2a6: role in metabolic activation of nasal toxicants.
      C Liu, X Zhuo, F J Gonzalez and X Ding
      Molecular Pharmacology October 1996, 50 (4) 781-788;

  6. Grimaldi, B

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  7. Gustafson, D L

    1. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
      D L Gustafson, H D Beall, E M Bolton, D Ross and C A Waldren
      Molecular Pharmacology October 1996, 50 (4) 728-735;

H

  1. Hadcock, J R

    1. Identification and characterization of novel somatostatin antagonists.
      R T Bass, B L Buckwalter, B P Patel, M H Pausch, L A Price, J Strnad and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 709-715;
    2. Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathway.
      L A Price, J Strnad, M H Pausch and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 829-837;

  2. Hales, T G

    1. Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors.
      E T Piros, P L Prather, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology October 1996, 50 (4) 947-956;

  3. Harpold, M M

    1. Functional coupling of rat group II metabotropic glutamate receptors to an omega-conotoxin GVIA-sensitive calcium channel in human embryonic kidney 293 cells.
      B A McCool, J P Pin, P F Brust, M M Harpold and D M Lovinger
      Molecular Pharmacology October 1996, 50 (4) 912-922;

  4. Hen, R

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  5. Herzmark, P

    1. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation.
      B R Conklin, P Herzmark, S Ishida, T A Voyno-Yasenetskaya, Y Sun, Z Farfel and H R Bourne
      Molecular Pharmacology October 1996, 50 (4) 885-890;

  6. Hjorth, S A

    1. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
      S A Hjorth, K Thirstrup and T W Schwartz
      Molecular Pharmacology October 1996, 50 (4) 977-984;

I

  1. Ichikawa, A

    1. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist.
      N Nishigaki, M Negishi and A Ichikawa
      Molecular Pharmacology October 1996, 50 (4) 1031-1037;

  2. Igarashi, K

    1. Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit.
      K Williams, J Chao, K Kashiwagi, T Masuko and K Igarashi
      Molecular Pharmacology October 1996, 50 (4) 701-708;

  3. Ishida, S

    1. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation.
      B R Conklin, P Herzmark, S Ishida, T A Voyno-Yasenetskaya, Y Sun, Z Farfel and H R Bourne
      Molecular Pharmacology October 1996, 50 (4) 885-890;

  4. Itoh, S

    1. Structural determinants of substrates for the prostaglandin transporter PGT.
      S Itoh, R Lu, Y Bao, J D Morrow, L J Roberts and V L Schuster
      Molecular Pharmacology October 1996, 50 (4) 736-742; DOI: https://doi.org/10.1124/mol.50.4.736

J

  1. Jacobitz, S

    1. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
      S Jacobitz, M M McLaughlin, G P Livi, M Burman and T J Torphy
      Molecular Pharmacology October 1996, 50 (4) 891-899;

  2. Jakobs, K H

    1. m3 Muscarinic receptor-induced and Gi-mediated heterologous potentiation of phospholipase C stimulation: role of phosphoinositide synthesis.
      M Schmidt, C Nehls, U Rümenapp and K H Jakobs
      Molecular Pharmacology October 1996, 50 (4) 1038-1046;
    2. Inhibition by toxin B of inositol phosphate formation induced by G protein-coupled and tyrosine kinase receptors in N1E-115 neuroblastoma cells: involvement of Rho proteins.
      C Zhang, M Schmidt, C von Eichei-Streiber and K H Jakobs
      Molecular Pharmacology October 1996, 50 (4) 864-869;

  3. Jia, Q

    1. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
      W E Robinson, M Cordeiro, S Abdel-Malek, Q Jia, S A Chow, M G Reinecke and W M Mitchell
      Molecular Pharmacology October 1996, 50 (4) 846-855;

  4. Jones, N A

    1. DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes.
      M MacFarlane, N A Jones, C Dive and G M Cohen
      Molecular Pharmacology October 1996, 50 (4) 900-911;

  5. Juliano, R L

    1. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
      S K Alahari, N M Dean, M H Fisher, R Delong, M Manoharan, K L Tivel and R L Juliano
      Molecular Pharmacology October 1996, 50 (4) 808-819;

K

  1. Kanzaki, M

    1. Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells.
      L Nie, H Mogami, M Kanzaki, H Shibata and I Kojima
      Molecular Pharmacology October 1996, 50 (4) 763-769;

  2. Kashiwagi, K

    1. Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit.
      K Williams, J Chao, K Kashiwagi, T Masuko and K Igarashi
      Molecular Pharmacology October 1996, 50 (4) 701-708;

  3. Kemp, M C

    1. Acemannan, a beta-(1,4)-acetylated mannan, induces nitric oxide production in macrophage cell line RAW 264.7.
      L Ramamoorthy, M C Kemp and I R Tizard
      Molecular Pharmacology October 1996, 50 (4) 878-884;

  4. Kennedy, A P

    1. Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe.
      A P Kennedy, K C Mangum, J Linden and J N Wells
      Molecular Pharmacology October 1996, 50 (4) 789-798;

  5. Kojima, I

    1. Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells.
      L Nie, H Mogami, M Kanzaki, H Shibata and I Kojima
      Molecular Pharmacology October 1996, 50 (4) 763-769;

  6. Komatsu, M

    1. Pituitary adenylate cyclase-activating peptide, carbachol, and glucose stimulate insulin release in the absence of an increase in intracellular Ca2+.
      M Komatsu, T Schermerhorn, S G Straub and G W Sharp
      Molecular Pharmacology October 1996, 50 (4) 1047-1054;

  7. Konidakis, G

    1. Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
      M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi
      Molecular Pharmacology October 1996, 50 (4) 985-993;

L

  1. Lau, Y T

    1. Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.
      S M Yu, S F Chen, Y T Lau, C M Yang and J C Chen
      Molecular Pharmacology October 1996, 50 (4) 1000-1009;

  2. Law, P Y

    1. Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors.
      E T Piros, P L Prather, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology October 1996, 50 (4) 947-956;

  3. Lechner, M C

    1. Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid.
      M C Wright, X J Wang, M Pimenta, V Ribeiro, A J Paine and M C Lechner
      Molecular Pharmacology October 1996, 50 (4) 856-863;

  4. Liebenhoff, U

    1. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
      A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal
      Molecular Pharmacology October 1996, 50 (4) 820-828;

  5. Linden, J

    1. Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe.
      A P Kennedy, K C Mangum, J Linden and J N Wells
      Molecular Pharmacology October 1996, 50 (4) 789-798;

  6. Liu, C

    1. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2a6: role in metabolic activation of nasal toxicants.
      C Liu, X Zhuo, F J Gonzalez and X Ding
      Molecular Pharmacology October 1996, 50 (4) 781-788;

  7. Livi, G P

    1. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
      S Jacobitz, M M McLaughlin, G P Livi, M Burman and T J Torphy
      Molecular Pharmacology October 1996, 50 (4) 891-899;

  8. Lovinger, D M

    1. Functional coupling of rat group II metabotropic glutamate receptors to an omega-conotoxin GVIA-sensitive calcium channel in human embryonic kidney 293 cells.
      B A McCool, J P Pin, P F Brust, M M Harpold and D M Lovinger
      Molecular Pharmacology October 1996, 50 (4) 912-922;

  9. Lu, J T

    1. Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.
      H Canton, R B Emeson, E L Barker, J R Backstrom, J T Lu, M S Chang and E Sanders-Bush
      Molecular Pharmacology October 1996, 50 (4) 799-807;

  10. Lu, R

    1. Structural determinants of substrates for the prostaglandin transporter PGT.
      S Itoh, R Lu, Y Bao, J D Morrow, L J Roberts and V L Schuster
      Molecular Pharmacology October 1996, 50 (4) 736-742; DOI: https://doi.org/10.1124/mol.50.4.736

M

  1. Maayani, S

    1. 5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism.
      K A Berg, S Maayani and W P Clarke
      Molecular Pharmacology October 1996, 50 (4) 1017-1023;

  2. MacFarlane, M

    1. DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes.
      M MacFarlane, N A Jones, C Dive and G M Cohen
      Molecular Pharmacology October 1996, 50 (4) 900-911;

  3. Makhlouf, G M

    1. Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle.
      K S Murthy and G M Makhlouf
      Molecular Pharmacology October 1996, 50 (4) 870-877;

  4. Mangum, K C

    1. Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe.
      A P Kennedy, K C Mangum, J Linden and J N Wells
      Molecular Pharmacology October 1996, 50 (4) 789-798;

  5. Manoharan, M

    1. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
      S K Alahari, N M Dean, M H Fisher, R Delong, M Manoharan, K L Tivel and R L Juliano
      Molecular Pharmacology October 1996, 50 (4) 808-819;

  6. Mary, S

    1. Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists.
      J Gomeza, S Mary, I Brabet, M L Parmentier, S Restituito, J Bockaert and J P Pin
      Molecular Pharmacology October 1996, 50 (4) 923-930;

  7. Massot, O

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  8. Masuko, T

    1. Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit.
      K Williams, J Chao, K Kashiwagi, T Masuko and K Igarashi
      Molecular Pharmacology October 1996, 50 (4) 701-708;

  9. McCool, B A

    1. Functional coupling of rat group II metabotropic glutamate receptors to an omega-conotoxin GVIA-sensitive calcium channel in human embryonic kidney 293 cells.
      B A McCool, J P Pin, P F Brust, M M Harpold and D M Lovinger
      Molecular Pharmacology October 1996, 50 (4) 912-922;

  10. McLaughlin, M M

    1. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
      S Jacobitz, M M McLaughlin, G P Livi, M Burman and T J Torphy
      Molecular Pharmacology October 1996, 50 (4) 891-899;

  11. Megaritis, G

    1. Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
      M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi
      Molecular Pharmacology October 1996, 50 (4) 985-993;

  12. Menta, E

    1. Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
      C Sissi, G Capranico, E Menta and M Palumbo
      Molecular Pharmacology October 1996, 50 (4) 838-845;

  13. Merkouris, M

    1. Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
      M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi
      Molecular Pharmacology October 1996, 50 (4) 985-993;

  14. Miledi, R

    1. Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist.
      D Ragozzino, R M Woodward, Y Murata, F Eusebi, L E Overman and R Miledi
      Molecular Pharmacology October 1996, 50 (4) 1024-1030;

  15. Milligan, G

    1. Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
      M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi
      Molecular Pharmacology October 1996, 50 (4) 985-993;

  16. Mitchell, W M

    1. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
      W E Robinson, M Cordeiro, S Abdel-Malek, Q Jia, S A Chow, M G Reinecke and W M Mitchell
      Molecular Pharmacology October 1996, 50 (4) 846-855;

  17. Mogami, H

    1. Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells.
      L Nie, H Mogami, M Kanzaki, H Shibata and I Kojima
      Molecular Pharmacology October 1996, 50 (4) 763-769;

  18. Morrow, J D

    1. Structural determinants of substrates for the prostaglandin transporter PGT.
      S Itoh, R Lu, Y Bao, J D Morrow, L J Roberts and V L Schuster
      Molecular Pharmacology October 1996, 50 (4) 736-742; DOI: https://doi.org/10.1124/mol.50.4.736

  19. Moya, E

    1. Block of high-threshold calcium channels by the synthetic polyamines sFTX-3.3 and FTX-3.3.
      T M Norris, E Moya, I S Blagbrough and M E Adams
      Molecular Pharmacology October 1996, 50 (4) 939-946;

  20. Müller, H

    1. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
      A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal
      Molecular Pharmacology October 1996, 50 (4) 820-828;

  21. Murata, Y

    1. Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist.
      D Ragozzino, R M Woodward, Y Murata, F Eusebi, L E Overman and R Miledi
      Molecular Pharmacology October 1996, 50 (4) 1024-1030;

  22. Murphy, T J

    1. Enhanced angiotensin receptor type 1 mRNA degradation and induction of polyribosomal mRNA binding proteins by angiotensin II in vascular smooth muscle cells.
      G Nickenig and T J Murphy
      Molecular Pharmacology October 1996, 50 (4) 743-751;

  23. Murthy, K S

    1. Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle.
      K S Murthy and G M Makhlouf
      Molecular Pharmacology October 1996, 50 (4) 870-877;

N

  1. Negishi, M

    1. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist.
      N Nishigaki, M Negishi and A Ichikawa
      Molecular Pharmacology October 1996, 50 (4) 1031-1037;

  2. Nehls, C

    1. m3 Muscarinic receptor-induced and Gi-mediated heterologous potentiation of phospholipase C stimulation: role of phosphoinositide synthesis.
      M Schmidt, C Nehls, U Rümenapp and K H Jakobs
      Molecular Pharmacology October 1996, 50 (4) 1038-1046;

  3. Neve, K A

    1. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors.
      V J Watts and K A Neve
      Molecular Pharmacology October 1996, 50 (4) 966-976;

  4. Nickenig, G

    1. Enhanced angiotensin receptor type 1 mRNA degradation and induction of polyribosomal mRNA binding proteins by angiotensin II in vascular smooth muscle cells.
      G Nickenig and T J Murphy
      Molecular Pharmacology October 1996, 50 (4) 743-751;

  5. Nie, L

    1. Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells.
      L Nie, H Mogami, M Kanzaki, H Shibata and I Kojima
      Molecular Pharmacology October 1996, 50 (4) 763-769;

  6. Nishigaki, N

    1. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist.
      N Nishigaki, M Negishi and A Ichikawa
      Molecular Pharmacology October 1996, 50 (4) 1031-1037;

  7. Norris, T M

    1. Block of high-threshold calcium channels by the synthetic polyamines sFTX-3.3 and FTX-3.3.
      T M Norris, E Moya, I S Blagbrough and M E Adams
      Molecular Pharmacology October 1996, 50 (4) 939-946;

O

  1. Oksche, A

    1. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
      A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal
      Molecular Pharmacology October 1996, 50 (4) 820-828;

  2. Oswald, R E

    1. Ligand-binding characteristics and related structural features of the expressed goldfish kainate receptors: identification of a conserved disulfide bond and three residues important for ligand binding.
      Z G Wo and R E Oswald
      Molecular Pharmacology October 1996, 50 (4) 770-780;

  3. Overman, L E

    1. Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist.
      D Ragozzino, R M Woodward, Y Murata, F Eusebi, L E Overman and R Miledi
      Molecular Pharmacology October 1996, 50 (4) 1024-1030;

P

  1. Paine, A J

    1. Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid.
      M C Wright, X J Wang, M Pimenta, V Ribeiro, A J Paine and M C Lechner
      Molecular Pharmacology October 1996, 50 (4) 856-863;

  2. Palumbo, M

    1. Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
      C Sissi, G Capranico, E Menta and M Palumbo
      Molecular Pharmacology October 1996, 50 (4) 838-845;

  3. Parmentier, M L

    1. Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists.
      J Gomeza, S Mary, I Brabet, M L Parmentier, S Restituito, J Bockaert and J P Pin
      Molecular Pharmacology October 1996, 50 (4) 923-930;

  4. Patel, B P

    1. Identification and characterization of novel somatostatin antagonists.
      R T Bass, B L Buckwalter, B P Patel, M H Pausch, L A Price, J Strnad and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 709-715;

  5. Pausch, M H

    1. Identification and characterization of novel somatostatin antagonists.
      R T Bass, B L Buckwalter, B P Patel, M H Pausch, L A Price, J Strnad and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 709-715;
    2. Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathway.
      L A Price, J Strnad, M H Pausch and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 829-837;

  6. Pimenta, M

    1. Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid.
      M C Wright, X J Wang, M Pimenta, V Ribeiro, A J Paine and M C Lechner
      Molecular Pharmacology October 1996, 50 (4) 856-863;

  7. Pin, J P

    1. Functional coupling of rat group II metabotropic glutamate receptors to an omega-conotoxin GVIA-sensitive calcium channel in human embryonic kidney 293 cells.
      B A McCool, J P Pin, P F Brust, M M Harpold and D M Lovinger
      Molecular Pharmacology October 1996, 50 (4) 912-922;
    2. Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists.
      J Gomeza, S Mary, I Brabet, M L Parmentier, S Restituito, J Bockaert and J P Pin
      Molecular Pharmacology October 1996, 50 (4) 923-930;

  8. Piros, E T

    1. Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors.
      E T Piros, P L Prather, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology October 1996, 50 (4) 947-956;

  9. Plantefol, M

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  10. Prather, P L

    1. Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors.
      E T Piros, P L Prather, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology October 1996, 50 (4) 947-956;

  11. Price, L A

    1. Identification and characterization of novel somatostatin antagonists.
      R T Bass, B L Buckwalter, B P Patel, M H Pausch, L A Price, J Strnad and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 709-715;
    2. Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathway.
      L A Price, J Strnad, M H Pausch and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 829-837;

  12. Prudhomme, N

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

R

  1. Ragozzino, D

    1. Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist.
      D Ragozzino, R M Woodward, Y Murata, F Eusebi, L E Overman and R Miledi
      Molecular Pharmacology October 1996, 50 (4) 1024-1030;

  2. Ramamoorthy, L

    1. Acemannan, a beta-(1,4)-acetylated mannan, induces nitric oxide production in macrophage cell line RAW 264.7.
      L Ramamoorthy, M C Kemp and I R Tizard
      Molecular Pharmacology October 1996, 50 (4) 878-884;

  3. Reinecke, M G

    1. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
      W E Robinson, M Cordeiro, S Abdel-Malek, Q Jia, S A Chow, M G Reinecke and W M Mitchell
      Molecular Pharmacology October 1996, 50 (4) 846-855;

  4. Restituito, S

    1. Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists.
      J Gomeza, S Mary, I Brabet, M L Parmentier, S Restituito, J Bockaert and J P Pin
      Molecular Pharmacology October 1996, 50 (4) 923-930;

  5. Ribeiro, V

    1. Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid.
      M C Wright, X J Wang, M Pimenta, V Ribeiro, A J Paine and M C Lechner
      Molecular Pharmacology October 1996, 50 (4) 856-863;

  6. Roberts, L J

    1. Structural determinants of substrates for the prostaglandin transporter PGT.
      S Itoh, R Lu, Y Bao, J D Morrow, L J Roberts and V L Schuster
      Molecular Pharmacology October 1996, 50 (4) 736-742; DOI: https://doi.org/10.1124/mol.50.4.736

  7. Robinson, W E

    1. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
      W E Robinson, M Cordeiro, S Abdel-Malek, Q Jia, S A Chow, M G Reinecke and W M Mitchell
      Molecular Pharmacology October 1996, 50 (4) 846-855;

  8. Rosenthal, W

    1. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
      A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal
      Molecular Pharmacology October 1996, 50 (4) 820-828;

  9. Ross, D

    1. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
      D L Gustafson, H D Beall, E M Bolton, D Ross and C A Waldren
      Molecular Pharmacology October 1996, 50 (4) 728-735;

  10. Rousseau, B

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  11. Rousselle, J C

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  12. Rümenapp, U

    1. m3 Muscarinic receptor-induced and Gi-mediated heterologous potentiation of phospholipase C stimulation: role of phosphoinositide synthesis.
      M Schmidt, C Nehls, U Rümenapp and K H Jakobs
      Molecular Pharmacology October 1996, 50 (4) 1038-1046;

  13. Rutz, C

    1. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
      A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal
      Molecular Pharmacology October 1996, 50 (4) 820-828;

S

  1. Sanders-Bush, E

    1. Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.
      H Canton, R B Emeson, E L Barker, J R Backstrom, J T Lu, M S Chang and E Sanders-Bush
      Molecular Pharmacology October 1996, 50 (4) 799-807;

  2. Schermerhorn, T

    1. Pituitary adenylate cyclase-activating peptide, carbachol, and glucose stimulate insulin release in the absence of an increase in intracellular Ca2+.
      M Komatsu, T Schermerhorn, S G Straub and G W Sharp
      Molecular Pharmacology October 1996, 50 (4) 1047-1054;

  3. Schmidt, M

    1. m3 Muscarinic receptor-induced and Gi-mediated heterologous potentiation of phospholipase C stimulation: role of phosphoinositide synthesis.
      M Schmidt, C Nehls, U Rümenapp and K H Jakobs
      Molecular Pharmacology October 1996, 50 (4) 1038-1046;
    2. Inhibition by toxin B of inositol phosphate formation induced by G protein-coupled and tyrosine kinase receptors in N1E-115 neuroblastoma cells: involvement of Rho proteins.
      C Zhang, M Schmidt, C von Eichei-Streiber and K H Jakobs
      Molecular Pharmacology October 1996, 50 (4) 864-869;

  4. Schonbrunn, A

    1. Agonist binding and protein kinase C activation stimulate phosphorylation of the gastrin-releasing peptide receptor at distinct sites.
      B Y Williams, Y Wang and A Schonbrunn
      Molecular Pharmacology October 1996, 50 (4) 716-727;

  5. Schülein, R

    1. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
      A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal
      Molecular Pharmacology October 1996, 50 (4) 820-828;

  6. Schuster, V L

    1. Structural determinants of substrates for the prostaglandin transporter PGT.
      S Itoh, R Lu, Y Bao, J D Morrow, L J Roberts and V L Schuster
      Molecular Pharmacology October 1996, 50 (4) 736-742; DOI: https://doi.org/10.1124/mol.50.4.736

  7. Schwartz, T W

    1. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
      S A Hjorth, K Thirstrup and T W Schwartz
      Molecular Pharmacology October 1996, 50 (4) 977-984;

  8. Seguin, L

    1. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
      O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
      Molecular Pharmacology October 1996, 50 (4) 752-762;

  9. Sharp, G W

    1. Pituitary adenylate cyclase-activating peptide, carbachol, and glucose stimulate insulin release in the absence of an increase in intracellular Ca2+.
      M Komatsu, T Schermerhorn, S G Straub and G W Sharp
      Molecular Pharmacology October 1996, 50 (4) 1047-1054;

  10. Shibata, H

    1. Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells.
      L Nie, H Mogami, M Kanzaki, H Shibata and I Kojima
      Molecular Pharmacology October 1996, 50 (4) 763-769;

  11. Sissi, C

    1. Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
      C Sissi, G Capranico, E Menta and M Palumbo
      Molecular Pharmacology October 1996, 50 (4) 838-845;

  12. Steinbach, J H

    1. Endogenous subunits can cause ambiguities in the pharmacology of exogenous gamma-aminobutyric acidA receptors expressed in human embryonic kidney 293 cells.
      S Ueno, C Zorumski, J Bracamontes and J H Steinbach
      Molecular Pharmacology October 1996, 50 (4) 931-938;

  13. Straub, S G

    1. Pituitary adenylate cyclase-activating peptide, carbachol, and glucose stimulate insulin release in the absence of an increase in intracellular Ca2+.
      M Komatsu, T Schermerhorn, S G Straub and G W Sharp
      Molecular Pharmacology October 1996, 50 (4) 1047-1054;

  14. Strnad, J

    1. Identification and characterization of novel somatostatin antagonists.
      R T Bass, B L Buckwalter, B P Patel, M H Pausch, L A Price, J Strnad and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 709-715;
    2. Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathway.
      L A Price, J Strnad, M H Pausch and J R Hadcock
      Molecular Pharmacology October 1996, 50 (4) 829-837;

  15. Sun, Y

    1. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation.
      B R Conklin, P Herzmark, S Ishida, T A Voyno-Yasenetskaya, Y Sun, Z Farfel and H R Bourne
      Molecular Pharmacology October 1996, 50 (4) 885-890;

T

  1. Thirstrup, K

    1. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
      S A Hjorth, K Thirstrup and T W Schwartz
      Molecular Pharmacology October 1996, 50 (4) 977-984;

  2. Tivel, K L

    1. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
      S K Alahari, N M Dean, M H Fisher, R Delong, M Manoharan, K L Tivel and R L Juliano
      Molecular Pharmacology October 1996, 50 (4) 808-819;

  3. Tizard, I R

    1. Acemannan, a beta-(1,4)-acetylated mannan, induces nitric oxide production in macrophage cell line RAW 264.7.
      L Ramamoorthy, M C Kemp and I R Tizard
      Molecular Pharmacology October 1996, 50 (4) 878-884;

  4. Torphy, T J

    1. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
      S Jacobitz, M M McLaughlin, G P Livi, M Burman and T J Torphy
      Molecular Pharmacology October 1996, 50 (4) 891-899;

  5. Tsyganskaya, M

    1. The antioxidant function of the physiological content of vitamin C.
      P A Glascott, M Tsyganskaya, E Gilfor, M A Zern and J L Farber
      Molecular Pharmacology October 1996, 50 (4) 994-999;

U

  1. Ueno, S

    1. Endogenous subunits can cause ambiguities in the pharmacology of exogenous gamma-aminobutyric acidA receptors expressed in human embryonic kidney 293 cells.
      S Ueno, C Zorumski, J Bracamontes and J H Steinbach
      Molecular Pharmacology October 1996, 50 (4) 931-938;

V

  1. von Eichei-Streiber, C

    1. Inhibition by toxin B of inositol phosphate formation induced by G protein-coupled and tyrosine kinase receptors in N1E-115 neuroblastoma cells: involvement of Rho proteins.
      C Zhang, M Schmidt, C von Eichei-Streiber and K H Jakobs
      Molecular Pharmacology October 1996, 50 (4) 864-869;

  2. Voyno-Yasenetskaya, T A

    1. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation.
      B R Conklin, P Herzmark, S Ishida, T A Voyno-Yasenetskaya, Y Sun, Z Farfel and H R Bourne
      Molecular Pharmacology October 1996, 50 (4) 885-890;

W

  1. Waldren, C A

    1. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
      D L Gustafson, H D Beall, E M Bolton, D Ross and C A Waldren
      Molecular Pharmacology October 1996, 50 (4) 728-735;

  2. Wang, X J

    1. Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid.
      M C Wright, X J Wang, M Pimenta, V Ribeiro, A J Paine and M C Lechner
      Molecular Pharmacology October 1996, 50 (4) 856-863;

  3. Wang, Y

    1. Agonist binding and protein kinase C activation stimulate phosphorylation of the gastrin-releasing peptide receptor at distinct sites.
      B Y Williams, Y Wang and A Schonbrunn
      Molecular Pharmacology October 1996, 50 (4) 716-727;

  4. Watts, V J

    1. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors.
      V J Watts and K A Neve
      Molecular Pharmacology October 1996, 50 (4) 966-976;

  5. Weight, F F

    1. Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino-terminal domain of the receptor.
      D Yu, L Zhang, J L Eiselé, D Bertrand, J P Changeux and F F Weight
      Molecular Pharmacology October 1996, 50 (4) 1010-1016;

  6. Wells, J N

    1. Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe.
      A P Kennedy, K C Mangum, J Linden and J N Wells
      Molecular Pharmacology October 1996, 50 (4) 789-798;

  7. Williams, B Y

    1. Agonist binding and protein kinase C activation stimulate phosphorylation of the gastrin-releasing peptide receptor at distinct sites.
      B Y Williams, Y Wang and A Schonbrunn
      Molecular Pharmacology October 1996, 50 (4) 716-727;

  8. Williams, K

    1. Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit.
      K Williams, J Chao, K Kashiwagi, T Masuko and K Igarashi
      Molecular Pharmacology October 1996, 50 (4) 701-708;

  9. Wo, Z G

    1. Ligand-binding characteristics and related structural features of the expressed goldfish kainate receptors: identification of a conserved disulfide bond and three residues important for ligand binding.
      Z G Wo and R E Oswald
      Molecular Pharmacology October 1996, 50 (4) 770-780;

  10. Woodward, R M

    1. Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist.
      D Ragozzino, R M Woodward, Y Murata, F Eusebi, L E Overman and R Miledi
      Molecular Pharmacology October 1996, 50 (4) 1024-1030;

  11. Wright, M C

    1. Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid.
      M C Wright, X J Wang, M Pimenta, V Ribeiro, A J Paine and M C Lechner
      Molecular Pharmacology October 1996, 50 (4) 856-863;

Y

  1. Yang, C M

    1. Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.
      S M Yu, S F Chen, Y T Lau, C M Yang and J C Chen
      Molecular Pharmacology October 1996, 50 (4) 1000-1009;

  2. Yu, D

    1. Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino-terminal domain of the receptor.
      D Yu, L Zhang, J L Eiselé, D Bertrand, J P Changeux and F F Weight
      Molecular Pharmacology October 1996, 50 (4) 1010-1016;

  3. Yu, S M

    1. Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.
      S M Yu, S F Chen, Y T Lau, C M Yang and J C Chen
      Molecular Pharmacology October 1996, 50 (4) 1000-1009;

Z

  1. Zern, M A

    1. The antioxidant function of the physiological content of vitamin C.
      P A Glascott, M Tsyganskaya, E Gilfor, M A Zern and J L Farber
      Molecular Pharmacology October 1996, 50 (4) 994-999;

  2. Zhang, C

    1. Inhibition by toxin B of inositol phosphate formation induced by G protein-coupled and tyrosine kinase receptors in N1E-115 neuroblastoma cells: involvement of Rho proteins.
      C Zhang, M Schmidt, C von Eichei-Streiber and K H Jakobs
      Molecular Pharmacology October 1996, 50 (4) 864-869;

  3. Zhang, L

    1. Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino-terminal domain of the receptor.
      D Yu, L Zhang, J L Eiselé, D Bertrand, J P Changeux and F F Weight
      Molecular Pharmacology October 1996, 50 (4) 1010-1016;

  4. Zhuo, X

    1. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2a6: role in metabolic activation of nasal toxicants.
      C Liu, X Zhuo, F J Gonzalez and X Ding
      Molecular Pharmacology October 1996, 50 (4) 781-788;

  5. Zioudrou, C

    1. Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
      M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi
      Molecular Pharmacology October 1996, 50 (4) 985-993;

  6. Zorumski, C

    1. Endogenous subunits can cause ambiguities in the pharmacology of exogenous gamma-aminobutyric acidA receptors expressed in human embryonic kidney 293 cells.
      S Ueno, C Zorumski, J Bracamontes and J H Steinbach
      Molecular Pharmacology October 1996, 50 (4) 931-938;
Back to top

In this issue

Advertisement